Your browser doesn't support javascript.
loading
Association of Time to Thrombolysis With Early Reperfusion After Alteplase and Tenecteplase in Patients With Large Vessel Occlusion.
Yogendrakumar, Vignan; Beharry, James; Churilov, Leonid; Pesavento, Lauren; Alidin, Khairuinnisa; Ugalde, Melissa; Weir, Louise; Mitchell, Peter J; Kleinig, Timothy J; Yassi, Nawaf; Thijs, Vincent N; Wu, Teddy Y; Brown, Helen; Dewey, Helen M; Wijeratne, Tissa; Yan, Bernard; Sharma, Gagan J; Desmond, Patricia; Parsons, Mark W; Donnan, Geoffrey A; Davis, Stephen M; Campbell, Bruce C V.
Affiliation
  • Yogendrakumar V; From the Department of Medicine and Neurology (V.Y., J.B., L.C., L.P., K.A., M.U., L.W., N.Y., B.Y., G.J.S., M.W.P., G.A.D., S.M.D., B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, Parkville, Australia; Department of Neurology (J.B., T.Y.W.), Christchurch Hospital, New Zealand; De
  • Beharry J; From the Department of Medicine and Neurology (V.Y., J.B., L.C., L.P., K.A., M.U., L.W., N.Y., B.Y., G.J.S., M.W.P., G.A.D., S.M.D., B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, Parkville, Australia; Department of Neurology (J.B., T.Y.W.), Christchurch Hospital, New Zealand; De
  • Churilov L; From the Department of Medicine and Neurology (V.Y., J.B., L.C., L.P., K.A., M.U., L.W., N.Y., B.Y., G.J.S., M.W.P., G.A.D., S.M.D., B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, Parkville, Australia; Department of Neurology (J.B., T.Y.W.), Christchurch Hospital, New Zealand; De
  • Pesavento L; From the Department of Medicine and Neurology (V.Y., J.B., L.C., L.P., K.A., M.U., L.W., N.Y., B.Y., G.J.S., M.W.P., G.A.D., S.M.D., B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, Parkville, Australia; Department of Neurology (J.B., T.Y.W.), Christchurch Hospital, New Zealand; De
  • Alidin K; From the Department of Medicine and Neurology (V.Y., J.B., L.C., L.P., K.A., M.U., L.W., N.Y., B.Y., G.J.S., M.W.P., G.A.D., S.M.D., B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, Parkville, Australia; Department of Neurology (J.B., T.Y.W.), Christchurch Hospital, New Zealand; De
  • Ugalde M; From the Department of Medicine and Neurology (V.Y., J.B., L.C., L.P., K.A., M.U., L.W., N.Y., B.Y., G.J.S., M.W.P., G.A.D., S.M.D., B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, Parkville, Australia; Department of Neurology (J.B., T.Y.W.), Christchurch Hospital, New Zealand; De
  • Weir L; From the Department of Medicine and Neurology (V.Y., J.B., L.C., L.P., K.A., M.U., L.W., N.Y., B.Y., G.J.S., M.W.P., G.A.D., S.M.D., B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, Parkville, Australia; Department of Neurology (J.B., T.Y.W.), Christchurch Hospital, New Zealand; De
  • Mitchell PJ; From the Department of Medicine and Neurology (V.Y., J.B., L.C., L.P., K.A., M.U., L.W., N.Y., B.Y., G.J.S., M.W.P., G.A.D., S.M.D., B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, Parkville, Australia; Department of Neurology (J.B., T.Y.W.), Christchurch Hospital, New Zealand; De
  • Kleinig TJ; From the Department of Medicine and Neurology (V.Y., J.B., L.C., L.P., K.A., M.U., L.W., N.Y., B.Y., G.J.S., M.W.P., G.A.D., S.M.D., B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, Parkville, Australia; Department of Neurology (J.B., T.Y.W.), Christchurch Hospital, New Zealand; De
  • Yassi N; From the Department of Medicine and Neurology (V.Y., J.B., L.C., L.P., K.A., M.U., L.W., N.Y., B.Y., G.J.S., M.W.P., G.A.D., S.M.D., B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, Parkville, Australia; Department of Neurology (J.B., T.Y.W.), Christchurch Hospital, New Zealand; De
  • Thijs VN; From the Department of Medicine and Neurology (V.Y., J.B., L.C., L.P., K.A., M.U., L.W., N.Y., B.Y., G.J.S., M.W.P., G.A.D., S.M.D., B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, Parkville, Australia; Department of Neurology (J.B., T.Y.W.), Christchurch Hospital, New Zealand; De
  • Wu TY; From the Department of Medicine and Neurology (V.Y., J.B., L.C., L.P., K.A., M.U., L.W., N.Y., B.Y., G.J.S., M.W.P., G.A.D., S.M.D., B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, Parkville, Australia; Department of Neurology (J.B., T.Y.W.), Christchurch Hospital, New Zealand; De
  • Brown H; From the Department of Medicine and Neurology (V.Y., J.B., L.C., L.P., K.A., M.U., L.W., N.Y., B.Y., G.J.S., M.W.P., G.A.D., S.M.D., B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, Parkville, Australia; Department of Neurology (J.B., T.Y.W.), Christchurch Hospital, New Zealand; De
  • Dewey HM; From the Department of Medicine and Neurology (V.Y., J.B., L.C., L.P., K.A., M.U., L.W., N.Y., B.Y., G.J.S., M.W.P., G.A.D., S.M.D., B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, Parkville, Australia; Department of Neurology (J.B., T.Y.W.), Christchurch Hospital, New Zealand; De
  • Wijeratne T; From the Department of Medicine and Neurology (V.Y., J.B., L.C., L.P., K.A., M.U., L.W., N.Y., B.Y., G.J.S., M.W.P., G.A.D., S.M.D., B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, Parkville, Australia; Department of Neurology (J.B., T.Y.W.), Christchurch Hospital, New Zealand; De
  • Yan B; From the Department of Medicine and Neurology (V.Y., J.B., L.C., L.P., K.A., M.U., L.W., N.Y., B.Y., G.J.S., M.W.P., G.A.D., S.M.D., B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, Parkville, Australia; Department of Neurology (J.B., T.Y.W.), Christchurch Hospital, New Zealand; De
  • Sharma GJ; From the Department of Medicine and Neurology (V.Y., J.B., L.C., L.P., K.A., M.U., L.W., N.Y., B.Y., G.J.S., M.W.P., G.A.D., S.M.D., B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, Parkville, Australia; Department of Neurology (J.B., T.Y.W.), Christchurch Hospital, New Zealand; De
  • Desmond P; From the Department of Medicine and Neurology (V.Y., J.B., L.C., L.P., K.A., M.U., L.W., N.Y., B.Y., G.J.S., M.W.P., G.A.D., S.M.D., B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, Parkville, Australia; Department of Neurology (J.B., T.Y.W.), Christchurch Hospital, New Zealand; De
  • Parsons MW; From the Department of Medicine and Neurology (V.Y., J.B., L.C., L.P., K.A., M.U., L.W., N.Y., B.Y., G.J.S., M.W.P., G.A.D., S.M.D., B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, Parkville, Australia; Department of Neurology (J.B., T.Y.W.), Christchurch Hospital, New Zealand; De
  • Donnan GA; From the Department of Medicine and Neurology (V.Y., J.B., L.C., L.P., K.A., M.U., L.W., N.Y., B.Y., G.J.S., M.W.P., G.A.D., S.M.D., B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, Parkville, Australia; Department of Neurology (J.B., T.Y.W.), Christchurch Hospital, New Zealand; De
  • Davis SM; From the Department of Medicine and Neurology (V.Y., J.B., L.C., L.P., K.A., M.U., L.W., N.Y., B.Y., G.J.S., M.W.P., G.A.D., S.M.D., B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, Parkville, Australia; Department of Neurology (J.B., T.Y.W.), Christchurch Hospital, New Zealand; De
  • Campbell BCV; From the Department of Medicine and Neurology (V.Y., J.B., L.C., L.P., K.A., M.U., L.W., N.Y., B.Y., G.J.S., M.W.P., G.A.D., S.M.D., B.C.V.C.), Melbourne Brain Centre at the Royal Melbourne Hospital, Parkville, Australia; Department of Neurology (J.B., T.Y.W.), Christchurch Hospital, New Zealand; De
Neurology ; 102(7): e209166, 2024 Apr 09.
Article in En | MEDLINE | ID: mdl-38502892
ABSTRACT
BACKGROUND AND

OBJECTIVES:

Early treatment with intravenous alteplase increases the probability of lytic-induced reperfusion in large vessel occlusion (LVO) patients. The relationship of tenecteplase-induced reperfusion and the timing of thrombolytic administration has not been explored. In this study, we performed a comparative analysis of tenecteplase and alteplase reperfusion rates and assessed their relationship to the time of thrombolytic administration.

METHODS:

Patients who were initially treated with a thrombolytic within 4.5 hours of symptom onset were pooled from the Royal Melbourne Stroke Registry, EXTEND-IA, EXTEND-IA TNK, and EXTEND-IA TNK part 2 trials. The primary outcome, thrombolytic-induced reperfusion, was defined as the absence of retrievable thrombus or >50% reperfusion at initial angiographic assessment (or repeat CT perfusion/angiography). We compared the treatment effect of tenecteplase and alteplase through fixed-effects Poisson regression modelling.

RESULTS:

Among 846 patients included in the primary analysis, early reperfusion was observed in 173 (20%) patients (tenecteplase 98/470 [21%], onset-to-thrombolytic time 132 minutes [interquartile range (IQR) 99-170], and thrombolytic-to-assessment time 61 minutes [IQR 39-96]; alteplase 75/376 [19%], onset-to-thrombolytic time 143 minutes [IQR 105-180], thrombolytic-to-assessment time 92 minutes [IQR 63-144]). Earlier onset-to-thrombolytic administration times were associated with an increased probability of thrombolytic-induced reperfusion in patients treated with either tenecteplase (adjusted risk ratio [aRR] 1.05 per 15 minutes [95% confidence interval (CI) 1.00-1.12] or alteplase (aRR 1.06 per 15 minutes [95% CI 1.00-1.13]). Tenecteplase remained associated with higher rates of reperfusion vs alteplase after adjustment for onset-to-thrombolytic time, occlusion site, thrombolytic-to-assessment time, and study as a fixed effect, (adjusted incidence rate ratio 1.41 [95% CI 1.02-1.93]). No significant treatment-by-time interaction was observed (p = 0.87).

DISCUSSION:

In patients with LVO presenting within 4.5 hours of symptom onset, earlier thrombolytic administration increased successful reperfusion rates. Compared with alteplase, tenecteplase was associated with a higher probability of lytic-induced reperfusion, independent of onset-to-lytic administration times. TRIAL REGISTRATION INFORMATION ClinicalTrials.gov Identifiers NCT02388061, NCT03340493. CLASSIFICATION OF EVIDENCE This study provides Class II evidence that among patients with LVO receiving a thrombolytic, reperfusion was more likely with tenecteplase than alteplase.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Brain Ischemia / Stroke Limits: Humans Language: En Journal: Neurology Year: 2024 Type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Brain Ischemia / Stroke Limits: Humans Language: En Journal: Neurology Year: 2024 Type: Article